Teva Pharmaceutical says it will defend claims it was involved in price- fixing in the US
Teva stocks fall after company said named in US price-fixing drug 'cartel' probe | The Times of Israel
Brussels issues €60m fine over drug price fixing | Financial Times
DOJ Charges Teva Pharmaceutical In Ongoing Generics Price-Fixing Probe | BioSpace
Teva reaches $925,000 settlement to resolve drug price-fixing claims - PMLiVE
The price-fixing claims look worse for Teva than they really are - U.S. News - Haaretz.com
Pharma Giant Teva Charged With Price-Fixing
Israel drugmaker Teva vows to fight US price-fixing lawsuit
Teva's U.S. Unit Charged in Generic-Drug Price-Fixing Probe - Bloomberg
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Teva, Glenmark accuse U.S. government of improperly expanding price-fixing case | FiercePharma
44 States Sue Drug Maker Teva, Alleging Price Fixing Scheme with 19 Other Firms
:max_bytes(150000):strip_icc()/TEVA-Chart-05152019-e44e5dbd6f964a0f9d7f5d1ec8c52d6a.png "Teva Hits Fibonacci Support on Concerns Over Lawsuit")
Teva Hits Fibonacci Support on Concerns Over Lawsuit
Teva said to 'walk away' from settlement talks in US price-fixing lawsuit | The Times of Israel
US charges Teva Pharmaceutical Industries Ltd in generic drugs price-fixing probe - The Economic Times
Teva faces price-fixing claim in US - Globes
Trillions - Teva Pharmaceuticals Becomes Seventh Company to be Charged in Generic Drug Price-Fixing Case
Generic drugmaker Teva indicted in alleged price-fixing conspiracy leading consumers to be overcharged by $350M - MedCity News
U.S. authorities expected to charge Teva in generic price-fixing probe
Trouble at Teva: US price-fixing lawsuit adds to generic giant's woes - Pharma Technology Focus | Issue 85 | August 2019
Teva charged in US price-fixing investigation | Financial Times
Teva charged with price fixing generic drugs - UPI.com
Teva Poised to Face U.S. Charges in Drug Price-Fixing Probe - Bloomberg
Teva orchestrated a massive price fixing scheme with generic competitors, states allege
